Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hemodialysis clearance of intravenously administered ribavirin.

Literature DB >> 2334164

Hemodialysis clearance of intravenously administered ribavirin.

T H Kramer¹, G G Gaar, C G Ray, L Minnich, J G Copeland, J D Connor.

Abstract

A patient with an implanted artificial heart, acute, anuric renal failure, and disseminated influenza virus type A infection received intravenous ribavirin. Drug elimination by hemodialysis was measured. Plasma dialysis clearance averaged 93.9 +/- 8.6 ml/min. The maximum amount of ribavirin removed from the body during one period of hemodialysis was 79.1 mg. Ribavirin is not removed in important quantities by hemodialysis.

Entities: Chemical Disease Species

Mesh：

Substances：
Ribonucleosides
Ribavirin

Year: 1990 PMID： 2334164 PMCID： PMC171624 DOI： 10.1128/AAC.34.3.489

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

9 in total

1. Treatment of influenza A (H1N1) virus infection with ribavirin aerosol.

Authors: S Z Wilson; B E Gilbert; J M Quarles; V Knight; H W McClung; R V Moore; R B Couch
Journal: Antimicrob Agents Chemother Date: 1984-08 Impact factor: 5.191

2. Ribavirin small-particle aerosol treatment of influenza.

Authors: V Knight; H W McClung; S Z Wilson; B K Waters; J M Quarles; R W Cameron; S E Greggs; J M Zerwas; R B Couch
Journal: Lancet Date: 1981-10-31 Impact factor: 79.321

3. Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin.

Authors: R K Austin; P E Trefts; M Hintz; J D Connor; M F Kagnoff
Journal: Antimicrob Agents Chemother Date: 1983-11 Impact factor: 5.191

4. Lassa fever. Effective therapy with ribavirin.

Authors: J B McCormick; I J King; P A Webb; C L Scribner; R B Craven; K M Johnson; L H Elliott; R Belmont-Williams
Journal: N Engl J Med Date: 1986-01-02 Impact factor: 91.245

5. Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome.

Authors: O L Laskin; J A Longstreth; C C Hart; D Scavuzzo; C M Kalman; J D Connor; R B Roberts
Journal: Clin Pharmacol Ther Date: 1987-05 Impact factor: 6.875

6. Hematological and bone marrow effects of ribavirin in rhesus monkeys.

Authors: P G Canonico; M D Kastello; T M Cosgriff; J C Donovan; P E Ross; C T Spears; E L Stephen
Journal: Toxicol Appl Pharmacol Date: 1984-06-30 Impact factor: 4.219

7. The use of intravenous ribavirin to treat influenza virus-associated acute myocarditis.

Authors: C G Ray; T B Icenogle; L L Minnich; J G Copeland; T M Grogan
Journal: J Infect Dis Date: 1989-05 Impact factor: 5.226

8. Ribavirin aerosol treatment of influenza B virus infection.

Authors: H W McClung; V Knight; B E Gilbert; S Z Wilson; J M Quarles; G W Divine
Journal: JAMA Date: 1983-05-20 Impact factor: 56.272

9. Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84.

Authors: B E Gilbert; S Z Wilson; V Knight; R B Couch; J M Quarles; L Dure; N Hayes; G Willis
Journal: Antimicrob Agents Chemother Date: 1985-03 Impact factor: 5.191

9 in total

6 in total

1. Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients.

Authors: Samir K Gupta; Bhavna Kantesaria; Paul Glue
Journal: Eur J Clin Pharmacol Date: 2011-10-27 Impact factor: 2.953

Review 2. Comparative pharmacokinetics of antiviral nucleoside analogues.

Authors: G D Morse; M J Shelton; A M O'Donnell
Journal: Clin Pharmacokinet Date: 1993-02 Impact factor: 6.447

3. Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment.

Authors: B J Brennan; K Wang; S Blotner; M O Magnusson; J J Wilkins; P Martin; J Solsky; K Nieforth; C Wat; J F Grippo
Journal: Antimicrob Agents Chemother Date: 2013-09-30 Impact factor: 5.191